推荐产品
product name
Ro-20-1724, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).
品質等級
化驗
≥98% (TLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
顏色
white
溶解度
DMSO: 20%
ethanol: 4%
運輸包裝
ambient
儲存溫度
10-30°C
InChI
1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
InChI 密鑰
PDMUULPVBYQBBK-UHFFFAOYSA-N
一般說明
A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
生化／生理作用
Cell permeable: yes
Primary Target
PDE IV
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM against PDE IV
警告
Toxicity: Irritant (B)
其他說明
Derian, C.K., et al. 1995. J. Immunol. 154, 308.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Mohammad Keyvanloo Shahrestanaki et al.
Research in pharmaceutical sciences, 14(2), 107-114 (2019-10-18)
Diabetes incidence showed ascending trends in recent years indicating urgent need for new therapeutic agents. Extracellular adenosine signaling showed promising results. However, role of its A3 receptor in pancreatic β-cells proliferation and insulin secretion is not well established. Thus, we
Pieter J Gaillard et al.
Methods in molecular biology (Clifton, N.J.), 437, 161-175 (2008-03-29)
Drug delivery across the blood-brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel
Alejandro Sánchez-Melgar et al.
Frontiers in neuroscience, 15, 702817-702817 (2021-09-21)
Gliomas are the most common and aggressive primary tumors in the central nervous system. The nucleoside adenosine is considered to be one major constituent within the tumor microenvironment. The adenosine level mainly depends on two enzymatic activities: 5'-nucleotidase (5'NT or
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门